WO2007053502A3 - Mutations and polymorphisms of hdac5 - Google Patents

Mutations and polymorphisms of hdac5 Download PDF

Info

Publication number
WO2007053502A3
WO2007053502A3 PCT/US2006/042187 US2006042187W WO2007053502A3 WO 2007053502 A3 WO2007053502 A3 WO 2007053502A3 US 2006042187 W US2006042187 W US 2006042187W WO 2007053502 A3 WO2007053502 A3 WO 2007053502A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac5
mutations
mutant
polymorphisms
various aspects
Prior art date
Application number
PCT/US2006/042187
Other languages
French (fr)
Other versions
WO2007053502A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007053502A2 publication Critical patent/WO2007053502A2/en
Publication of WO2007053502A3 publication Critical patent/WO2007053502A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC5 gene. The invention provides new HDAC5 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC5 mutations of the invention, expression vectors encoding the HDAC5 mutant polypeptides of the invention and organisms that express the HDAC5 mutant and polymorphic polynucleotides and/or HDAC5 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC5 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/042187 2005-11-01 2006-10-30 Mutations and polymorphisms of hdac5 WO2007053502A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73237205P 2005-11-01 2005-11-01
US60/732,372 2005-11-01

Publications (2)

Publication Number Publication Date
WO2007053502A2 WO2007053502A2 (en) 2007-05-10
WO2007053502A3 true WO2007053502A3 (en) 2008-03-20

Family

ID=38006411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042187 WO2007053502A2 (en) 2005-11-01 2006-10-30 Mutations and polymorphisms of hdac5

Country Status (1)

Country Link
WO (1) WO2007053502A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2423154B1 (en) * 2012-03-12 2014-07-15 Universidad Autónoma de Madrid In vitro method of prognosis of liver cirrhosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ACHARYA MILIN R ET AL: "Rational development of histone deacetylase inhibitors as anticancer agents: A review", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 68, no. 4, 2005, pages 917 - 932, XP002423309, ISSN: 0026-895X *
GEORGE ET AL: "COMBINATION OF THE HISTONE DEACETYLASE INHIBITOR LBH589 AND THE HSP90 INHIBITOR 17-AAG IS HIGHLY ACTIVE AGAINST HUMAN CML-BC CELLS AND AML CELLS WITH ACTIVATING MUTATION OF FLT-3", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 105, no. 4, 28 October 2004 (2004-10-28), pages 1768 - 1776, XP008075090, ISSN: 0006-4971 *
MAHLKNECHT^A U ET AL: "Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5)", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1493, no. 3, 2 October 2000 (2000-10-02), pages 342 - 348, XP004275779, ISSN: 0167-4781 *
MAI ANTONELLO ET AL: "HISTONE DEACETYLATION IN EPIGENETICS: AN ATTRACTIVE TARGET FOR ANTICANCER THERAPY", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 25, no. 3, May 2005 (2005-05-01), pages 261 - 309, XP009075075, ISSN: 0198-6325 *
MONNERET C: "Histone deacetylase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 40, no. 1, January 2005 (2005-01-01), pages 1 - 13, XP004708959, ISSN: 0223-5234 *
PARK J M ET AL: "no association between polymorphisms in the histone deacetylase genes and the risk of lung cancer", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 14, no. 7, July 2005 (2005-07-01), pages 1841 - 1843, XP002424811, ISSN: 1055-9965 *
REMISZEWSKI S W ET AL: "N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]me thyl]phenyl]-2-propenamide (NVP-LAQ824)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, 2003, pages 4609 - 4624, XP002414496, ISSN: 0022-2623 *
SCANLAN M J ET AL: "Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, no. 14, 15 July 2002 (2002-07-15), pages 4041 - 4047, XP002324717, ISSN: 0008-5472 *
WADE P A: "Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.", HUMAN MOLECULAR GENETICS APR 2001, vol. 10, no. 7, April 2001 (2001-04-01), pages 693 - 698, XP002463805, ISSN: 0964-6906 *

Also Published As

Publication number Publication date
WO2007053502A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2005082042A3 (en) Therapeutic methods employing nitric oxide precursors
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
WO2001031007A3 (en) Nucleic acid molecules derived from rat brain and programmed cell death models
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
MX2010006484A (en) Compositions and methods of detecting tiabs.
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
EP2189541A3 (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
BR0111473A (en) Methods for screening an individual for glycogen storage disease, for screening an individual for pomp disease, for monitoring the clinical condition of an individual with pomp disease, to estimate the efficacy of a therapeutic regimen for an individual with disease pompe and to determine the concentration of an oligosaccharide in a biological sample
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2006081248A3 (en) Cancer markers and detection methods
MX2009001937A (en) Biomarkers for alzheimer's disease progression.
TW200716764A (en) Bladder cancer biomarkers and uses thereof
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2006003414A3 (en) Biomarkers of alzheimer's disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06836621

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06836621

Country of ref document: EP

Kind code of ref document: A2